Abstract
Detecting and characterizing blood clots (hematomas) in dogs is crucial for timely treatment. This review explores the potential of low-field magnetic resonance imaging (MRI) in assessing time-dependent changes in canine blood clots. We analyze a key study evaluating signal intensity variations in blood samples at different time points. While limitations exist, the findings suggest that low-field MRI may offer valuable insights into clot development and age estimation, potentially aiding diagnosis and treatment planning.
Introduction
Blood clots, or hematomas, can occur in dogs due to injuries, surgeries, or underlying health conditions. Prompt diagnosis and management are crucial to prevent complications. Conventional diagnostic tools like X-rays and ultrasounds have limitations in characterizing blood clots. Magnetic resonance imaging (MRI) offers a more detailed view but often requires high-field strength magnets, making it expensive and less accessible in veterinary settings. Low-field MRI presents a potential alternative. This review examines a study investigating the use of low-field MRI to assess time-dependent changes in canine blood clots, offering insights into its diagnostic potential.
Time-Dependent Signal Intensity and Clot Characterization
The study by Jeong et al. (2015) [1] evaluated the signal intensity of canine blood clots in low-field MRI scans over 30 days. Blood samples from healthy dogs were analyzed, revealing distinct changes in signal intensity based on clot composition and age. Heterogeneous clots, likely containing a mix of cellular components and fluids, displayed layered structures with varying intensity on MRI. These layers remained relatively stable after day 13, suggesting the potential for identifying older clots. The margination (border) of the clot and surrounding plasma also showed significant changes over time.
Limitations and Future Directions
Despite the promising findings, the study highlights limitations. The in vitro nature of the experiment doesn't account for the complexities of in vivo blood flow and clot formation. Accurately translating signal intensity changes to specific clot age requires further investigation. Future research needs to explore how low-field MRI performs in diagnosing and differentiating blood clots in live animals compared to traditional methods.
Conclusion
This review sheds light on the potential of low-field MRI for assessing time-dependent characteristics of canine blood clots. The study by Jeong et al. (2015) [1] provides a valuable starting point, suggesting that low-field MRI may offer insights into clot development and age estimation, potentially aiding in canine hematoma diagnosis and treatment planning. Further research is necessary to validate these findings in vivo and explore the full clinical utility of low-field MRI in veterinary medicine.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
New surgical method shows promising results for cervical cancer treatment
2.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Public Health Strategies for Improving Cancer Survivorship Support Systems
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Red Cell Deformability as a Target in Critical Illness
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation